生物技术公司Disco Pharmaceuticals近日宣布与全球生物制药巨头安进（Amgen）签署一项重要许可协议。该合作旨在加速开发针对癌症表面组的新型靶向疗法，通过整合双方在肿瘤免疫学和药物研发领域的专长，探索创新治疗途径。此次合作有望为癌症患者带来更精准、有效的治疗方案，标志着表面组学研究在临床转化领域迈出关键一步。
生物技术公司Disco Pharmaceuticals近日宣布与全球生物制药巨头安进（Amgen）签署一项重要许可协议。该合作旨在加速开发针对癌症表面组的新型靶向疗法，通过整合双方在肿瘤免疫学和药物研发领域的专长，探索创新治疗途径。此次合作有望为癌症患者带来更精准、有效的治疗方案，标志着表面组学研究在临床转化领域迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.